BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 184 filers reported holding BRIDGEBIO PHARMA INC in Q3 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,676,705 | +164.4% | 1,277,084 | +72.5% | 0.09% | +184.4% |
| Q2 2023 | $12,734,725 | -1.5% | 740,391 | -5.0% | 0.03% | -13.5% |
| Q1 2023 | $12,924,773 | +160.5% | 779,540 | +19.7% | 0.04% | +131.2% |
| Q4 2022 | $4,962,228 | -42.7% | 651,211 | -25.3% | 0.02% | -44.8% |
| Q3 2022 | $8,660,000 | +530.7% | 871,207 | +476.0% | 0.03% | +480.0% |
| Q2 2022 | $1,373,000 | -73.5% | 151,263 | -70.3% | 0.01% | -66.7% |
| Q1 2022 | $5,172,000 | -48.8% | 509,548 | -15.9% | 0.02% | -31.8% |
| Q4 2021 | $10,111,000 | +361.7% | 606,189 | +1197.4% | 0.02% | +340.0% |
| Q3 2021 | $2,190,000 | +129.1% | 46,722 | +198.0% | 0.01% | +150.0% |
| Q2 2021 | $956,000 | -96.8% | 15,679 | -96.8% | 0.00% | -97.4% |
| Q1 2021 | $29,804,000 | +154.6% | 483,828 | +194.0% | 0.08% | +129.4% |
| Q4 2020 | $11,704,000 | +136.0% | 164,589 | +24.5% | 0.03% | +88.9% |
| Q3 2020 | $4,959,000 | – | 132,175 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |